Keyphrases
Albumin
14%
C-peptide
14%
Cardiac Events
14%
Fasting Plasma Glucose
42%
Gamma-glutamyltransferase
14%
Glibenclamide
14%
Gliclazide
14%
Glimepiride
14%
Glipizide
14%
Glycemic Control
100%
Hemoglobin A1c (HbA1c)
42%
Hepatotoxicity
14%
Hypoglycemia
14%
Insulin
14%
Insulin Sensitizers
14%
Intention-to-treat Analysis
14%
LDL Cholesterol
28%
Lipids
14%
Non-esterified Fatty Acids
14%
Placebo
28%
Rosiglitazone
100%
Sulfonylurea
71%
Sulfonylurea Therapy
100%
Thiazolidinediones
14%
Treatment Group
14%
Twice Daily
14%
Type 2 Diabetic Patients
100%
INIS
albumins
16%
cholesterol
33%
comparative evaluations
16%
control
100%
doses
100%
fasting
50%
fatty acids
16%
glucose
50%
hemoglobin
50%
insulin
33%
levels
16%
lipids
16%
males
16%
patients
100%
peptides
16%
plasma
50%
safety
33%
therapy
100%
Pharmacology, Toxicology and Pharmaceutical Science
C Peptide
14%
Carbutamide
14%
Diabetes Mellitus
100%
Fatty Acid
14%
Gamma Glutamyltransferase
14%
Glibenclamide
14%
Gliclazide
14%
Glimepiride
14%
Glipizide
14%
Hemoglobin A
42%
Hepatotoxicity
14%
High Density Lipoprotein Cholesterol
14%
Hypoglycemia
14%
Low Density Lipoprotein Cholesterol
14%
Non Insulin Dependent Diabetes Mellitus
14%
Placebo
28%
Rosiglitazone
100%
Sulfonylurea
100%
Thiazolidinedione
14%